Desmond-Hellmann discusses the drug development process and shares her experience with the targeted cancer therapeutic, Herceptin.
An oncologist and leader in biotechnology, Susan Desmond-Hellmann is currently Chancellor of the University of California San Francisco. Prior to joining UCSF, Desmond-Hellmann spent 14 years at Genentech where she served as President, Product Development from 2004-2009. Under her direction, Genentech became the nation’s No. 1 producer of anti-cancer drug treatments. Continue Reading